This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?

PROactive Study: PROspective pioglitAzone Clinical Trial In macroVascular Events

Diabetic Department, Victoria Hospital, Kirkcaldy, Fife, KY2 5AH, Scotland, UK, jackie.wallace{at}faht.scot.nhs.uk

Key Words: pioglitazone • type 2 diabetes mellitus • macrovascular events.

References

• Campbell IW Pioglitazone - an oral antidiabetic agent and metabolic syndrome modulator. Can therapy translate into practice?Br J Diabetes Vasc Dis 2005;5:209-16.[Abstract/Free Full Text]
• McCallum RW, Fisher M. From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes. Br J Diabetes Vasc Dis 2005;5:218-25.[Abstract/Free Full Text]
• Charbonnel B., Dormandy J., Erdmann E., Massi-Benedetti M., Skene A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27:1647-53.[Abstract/Free Full Text]
• Staels B. PPAR and atherosclerosis. Curr Med Res Opin 2005;21(suppl 1):S13-S20.
• Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidaemia. Diabetes Care 2005;28:1547-54.[Abstract/Free Full Text]
• Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703.[Abstract/Free Full Text]
• Belcher G., Lambert C., Goh KL et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J CLin Pract 2004;58:833-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Karter AJ, Ahmed AT, Liu J., Moffet HH, Parker MM Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22:986-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 5, 272-274 (2005)
DOI: 10.1177/14746514050050050601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?